Biomarkers are usually blood test to know if cancer could be present or to monitor staging of the certain cancer. Now there are optical biomarkers for Barrett's esophagus. These biomarkers are derived from nondysplastic metaplastic cells which can detect high grade dysplasia and adenocarinoma from Barretts esophagus. This study was presented at the Gastrointestinal Cancers Symposium which was sponsored by the American Society of Clinical Oncology. These optical biomarkers could be uses on select patients who should go on to high resolution endoscopy and also who would require ablation therapy.
“Our biggest challenge is to identify high-risk patients who look normal
on [conventional] endoscopy. The optical biomarkers can distinguish
between BE without neoplastic changes from those with dysplasia,” stated
Randall E. Brand, MD, University of Pittsburgh School of Medicine,
Pennsylvania. “SLQPM (spatial-domain low-coherence quantitative phase
microscopy)-derived biomarkers provide a promising approach for
differentiation of dysplastic/ neoplastic BE from nondysplastic
intraepithelial metaplasia. Future studies are warranted to expand our
study population and develop additional new optical biomarkers to
improve on current sensitivity and specificity and validate our
Because it is known that BE can progress from low-grade to high-grade
dysplasia and invasive cancer, BE patients typically undergo endoscopic
surveillance at 1- to 3- year intervals. Standard protocol includes
four-quadrant random biopsies every 1-2 cm along the entire length of
BE. Brand pointed out that random sampling is challenging due to the
inability to differentiate patients with nondysplastic BE from those who
have occult high-grade dysplasia, or who will progress to high-grade
dysplasia or esophageal cancer. Therefore, optical biomarkers have the
potential to fill an unmet need.
SL-QPM utilizes broadband light source, a microscope, and a tissue
specimen. Cell changes are shown by light reflectance. The retrospective
study reported at the symposium included archived specimens from 33
controls with BE and no cancer and 21 samples with high-grade dysplasia.
The study also included six samples from patients with esophageal
Using optical signatures, three biomarkers were identified that can
discriminate between cells with neoplasia and those with no neoplasia. A
prediction model combining the three significant optical biomarkers had
89% sensitivity, 76% specificity, and 87% accuracy for distinguishing
BE from high-grade dysplasia or esophageal cancer.
“If subsequent testing [of these optical biomarkers] proves successful,
our approach could lead to simpler and more effective ways of
monitoring patients with BE. Such a monitoring program would identify a
subset of high-risk BE patients who require more intensive surveillance
with high-resolution endoscopic imaging, and who could also be
candidates for therapy to destroy the precancerous tissue. We need a way
to select patients for high-resolution imaging—not all centers are
equipped to do that,” Brand said.
Goblet cells are stained blue in Barrett's Esophogus
The moderator of the press conference where these findings were
discussed, Morton Kahlenberg, MD, said, “This is an exciting study
suggesting that the biomarkers may be an additional test that can
identify patients who harbor cells that will progress and a basis for
modifying treatment.” Kahlenberg is medical director of Surgical
Oncology Associates of South Texas in San Antonio.
For more informationhttp://www.onclive.com/publications/Oncology-live/2012/march-2012/Optical-Biomarkers-Distinguish-Risk-Levels-in-Barretts-Esophagus